Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Receivables (2016 - 2026)

Dexcom has reported Receivables over the past 17 years, most recently at $1.1 billion for Q1 2026.

  • Quarterly Receivables fell 5.5% to $1.1 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Mar 2026, down 5.5% year-over-year, with the annual reading at $1.2 billion for FY2025, 20.78% up from the prior year.
  • Receivables was $1.1 billion for Q1 2026 at Dexcom, down from $1.2 billion in the prior quarter.
  • Over five years, Receivables peaked at $1.4 billion in Q2 2025 and troughed at $554.8 million in Q1 2022.
  • The 5-year median for Receivables is $981.9 million (2023), against an average of $917.0 million.
  • Year-over-year, Receivables soared 53.12% in 2024 and then dropped 5.5% in 2026.
  • A 5-year view of Receivables shows it stood at $722.3 million in 2022, then soared by 35.94% to $981.9 million in 2023, then grew by 3.97% to $1.0 billion in 2024, then rose by 20.78% to $1.2 billion in 2025, then dropped by 10.34% to $1.1 billion in 2026.
  • Per Business Quant, the three most recent readings for DXCM's Receivables are $1.1 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.1 billion (Q3 2025).